# Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

> **NCT02858401** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 48 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Vesatolimod
- **DRUG:** Placebo
- **DRUG:** ARV regimen

## Key facts

- **NCT ID:** NCT02858401
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-29
- **Primary completion:** 2019-02-14
- **Final completion:** 2019-02-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858401, "Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02858401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*